Wei Mai Medical Completes Nearly RMB 100 Million Strategic Financing to Accelerate Smart Healthcare Ecosystem Expansion

Recently, Wismed (Wismed Intelligent Technology (Beijing) Co., Ltd., hereinafter referred to as "Wismed Medical") announced the completion of a strategic financing round amounting to nearly RMB 100 million. This round was directly funded by Zhonghong Pulin Group Co., Ltd. (hereinafter referred to as "Zhonghong Medical," stock code: 300981). The raised funds will be primarily used to accelerate technological research and development and product registration processes, as well as to expand into new domestic and overseas markets.

Wismed, established in 2014, is a company dedicated toDigital Vital Signs Management Solutionan innovative healthcare enterprise. The company has gathered numerous elites in the fields of medical technology and intelligence, leveraging its profound technical expertise and innovative thinking to continuously drive the intelligent transformation and upgrading of the healthcare industry, with a commitment to becoming“Pioneer of the Digital Smart Healthcare Ecosystem”。

Zhonghong Pulin Group is a member enterprise of Xiamen ITG Holding Group, a Fortune Global 500 company.In March 2024, Zhonghong Pulin Group entered into a business partnership with Wismed. Now, Zhonghong Pulin Group has officially taken an equity stake in Wismed, marking the upgrade of their collaboration from a “business partnership” to a “strategic partnership.”

This capital injection decision stems from the deep alignment between the two parties across multiple dimensions, including R&D capabilities, industrialization layout, and strategic synergy. Moving forward, they will deepen their collaboration in sales channels, technology, and branding, joining hands to usher in a new era of digital vital signs management.

2024 was Wismed’s “Year of Breakthrough.”

First, following the perioperative temperature management system, Wismed’s independently developedWireless Temperature Monitoring System for Ward ThermometryOfficially approved for the Class II Medical Device Registration Certificate. This system is designed to enhance temperature management capabilities for ward patients, marking Wismed’s formal launch of clinical services for ward temperature monitoring.Achieving comprehensive expansion from perioperative temperature management to multi-scenario temperature management.

Wireless Temperature Monitoring System SetDisposable Smart Wearable Temperature ElectrodeandCentral Smart Nursing Management Systemintegrated into a single unit, it enables remote, real-time monitoring of patients’ body temperature. Healthcare professionals can rapidly and accurately obtain temperature data without frequently entering patient rooms, and the system can automatically export nursing records. This significantly enhances work efficiency, reduces the risk of cross-infection, and provides patients with safer and more convenient nursing care.

Wireless Body Temperature Monitoring System

Image provided by Wismed

In addition to temperature management, the wireless ward temperature monitoring system integrates functional modules such as fall detection alerts, gait analysis, and real-time location tracking, enabling real-time, dynamic monitoring of patients’ various activity statuses. Upon detecting abnormal fall movements, the system immediately triggers an alarm mechanism to promptly notify medical staff for intervention. This feature provides more comprehensive and reliable safety assurance for elderly, mobility-impaired, or critically ill patients, demonstrating significant application value in clinical nursing.and Professional Significance。

Panoramic View of Wireless Body Temperature Monitoring Systems

Image courtesy of Wismed

Secondly, Wismed continues to exert efforts in the field of digital smart healthcare ecosystems.Established digital platforms for anesthesia quality control management, neurological disease management systems, and full-course cardiovascular disease management.. These platforms deeply empower clinical pathway management, achieving significant “from-scratch” breakthroughs in areas such as perioperative care, neurological disorders, and cardiovascular diseases. Owing to their innovation and practicality, Wismed’s digital platform has gained high recognition from leading benchmark hospitals in China, rapidly achieving coverage across medical consortium hospitals and nationwide, thereby strongly driving the industry’s digital transformation.

In 2024, in the field of cardiovascular disease management, Wismed significantly upgraded its solutions,Upgraded from the previous generation’s full-course digital solution to an integrated comprehensive management system for the entire disease course, combining assessment, monitoring, training, and rehabilitation functions.. Regarding this upgrade,Yin Shichang, Founder and CEO of Wismed, pointed out: “The assessment and training systems in traditional cardiovascular rehabilitation programs cost millions of yuan, which greatly limits their adoption by primary healthcare institutions. Our independently developed holistic solution, integrating wearable devices, training equipment, and software systems, reduces the cost to tens of thousands of yuan, significantly lowering the procurement threshold for primary healthcare institutions and effectively promoting the decentralization of high-quality medical resources.”

Currently, Wismed is activelyChinese PLA General Hospital, Renmin Hospital of Wuhan University, Beijing Anzhen Hospital Affiliated to Capital Medical University...and other large Grade A tertiary hospitals, establishing more than ten national model hospitals. Through these collaborations, Wismed has accumulated extensive clinical experience and further optimized its solutions. In the future, these benchmark solutions from Grade A tertiary hospitals will be rapidly promoted across medical consortiums and nationwide, effectively enhancing primary care diagnostic and treatment capabilities, enabling a broad base of patients at the grassroots level to access high-quality medical services, and promoting the balanced development of healthcare resources.

Following multiple breakthroughs in serious medical scenarios, Wismed has capitalized on this momentum to successfully penetrate the consumer healthcare market.In 2024, its home temperature-monitoring product, “Maike Wuyou,” successfully obtained medical device registration certification and was launched on the market. This achievement marks a significant expansion of Wismed from in-hospital to out-of-hospital scenarios.

Home Temperature Monitoring Product “Maike Wuyou”

Image courtesy of Wismed

“Relying solely on a single temperature-measuring product is insufficient to thoroughly address childhood fever; this requires close collaboration with doctors and hospitals,” stated Yin Shichang.Therefore, the more critical positioning of this home temperature-monitoring product lies in bridging in-hospital and out-of-hospital scenarios to create a closed-loop service.

In in-hospital settings, this product enables continuous temperature monitoring for patients in pediatric outpatient clinics and fever clinics. The collected temperature data serves as a critical reference for physicians during diagnosis. In out-of-hospital settings, patients’ families can leverage Wismed’s internet hospital platform, launched in 2024, to facilitate remote post-consultation monitoring and efficient doctor-patient interaction. Yin Shichang stated, “In the future, Wismed plans to integrate more medical functions and information into its internet hospital system, thereby promoting the rational allocation and efficient utilization of healthcare resources.”

For Wismed, the integration of home temperature-monitoring products with internet hospitals holds significant strategic importance. The company can directly reach its target consumer base through hospitals and physicians, leveraging the practical value of its products to successfully achieve commercial conversion from serious medical settings to consumer healthcare.

Amid the wave of digital transformation, Wismed’s “breakthrough” is also reflected in the construction of a smart healthcare ecosystem.By building platforms such as Wheat Innovation, Wheat Smart Connect, Wheat AI, and Wheat Ecosystem, Wismed has achieved data collection, data interoperability, and artificial intelligence analysis.Successfully established a comprehensive smart healthcare ecosystem spanning from hospitals to homes and from individual institutions to medical consortia.This system not only provides hospitals with efficient and precise digital healthcare solutions, but also brings medical wearable technology from hospitals into the lives of ordinary people, accelerating technological innovation and advancing the cause of human health.

In 2024, the chill in China’s medical device market persisted, with total tender amounts and the performance of multiple listed companies declining sharply as the market continued to contract. Amid this severe industry environment, Wismed achieved counter-trend growth in its business performance by leveraging its strong R&D capabilities and innovative solution concepts.

Currently, Wismed’s products and services have reached more than 1,000 hospitals across over 30 provinces and municipalities in China, cumulatively serving more than 10 million patients. Notably, the “Provincial Anesthesia Quality Control Cloud Platform,” spearheaded by Wismed, has been deployed in 22 provinces and municipalities nationwide.By collecting and analyzing anesthesia-related medical data, the platform standardizes clinical anesthesia practices, effectively optimizes regional anesthesia care quality, strengthens specialty management, and significantly empowers the improvement of regional healthcare quality. Meanwhile, the platform’s widespread adoption has created more opportunities for Wismed to deepen its collaborations with hospitals, enhancing the market competitiveness and penetration rate of its products, and further solidifying Wismed’s position within the industry.

2025 will be Wismed’s “Year One of Global Expansion.”

Yin Shichang stated that Wismed has fully launched its “Global Expansion Initiative.” In the initial phase, by leveraging Zhonghong Pulin Group’s mature overseas channel resources, the company will focus on expanding into markets in South America, the Middle East, and Southeast Asia. It aims to establish global benchmark cases using temperature management solutions as a breakthrough point, thereby accelerating the deployment of its products overseas.In the future, we will gradually achieve internationalization across our entire product line, providing cost-effective and rapidly deployable solutions for temperature management, remote vital signs monitoring, and full-course management of cardiovascular diseases abroad.

Looking ahead, Wismed will continue to uphold its vision of “creating the most comfortable healthcare environment” and adhere to its core values of “customer first, resilience and accountability, pursuit of excellence, and collaborative innovation,” constantly driving the development and innovation of intelligent healthcare. Centered on intelligent digital technologies, the company is committed to building a wireless digital healthcare ecosystem, contributing to the establishment of the future digital healthcare ecosystem.

Yin Shichang, Founder and CEO of WismedStatement: This round of financing marks a significant milestone for Wismed in deepening strategic synergy and accelerating its ecosystem layout. We extend our gratitude to Zhonghong Pulin Group, as well as new and existing investors, for their trust and confidence. This investment not only affirms our technological prowess and industrialization capabilities but also demonstrates the shared commitment of both parties to explore the value of medical innovation. Moving forward, we will integrate resources with greater openness to drive the global deployment of solutions in temperature management and cardiovascular rehabilitation. Simultaneously, leveraging our internet hospital and digital platforms, we aim to establish a seamless service loop connecting in-hospital and out-of-hospital care. We look forward to working hand in hand with our partners to reshape medical efficiency through technological innovation and create long-term value through ecosystem synergy, ensuring that smart healthcare truly benefits every patient and helps propel China’s medical industry to new heights.

Yang Hao, President of Zhonghong Pulin GroupStatement: The anesthesia and critical care sector is a current key focus for the Innovation Incubation Division of Zhonghong Pulin Group. The strategic partnership with Wismed marks a critical step forward in this field, representing a strategically significant move. Through this strategic investment, Zhonghong Pulin has deepened its ties with Wismed beyond its existing role as a product distributor, fostering greater mutual benefit and trust while leveraging each party’s strengths to offset weaknesses. Moving forward, we will jointly expand into products for ward and home settings, co-building a digital smart healthcare ecosystem that spans both in-hospital and out-of-hospital environments. By pursuing diversified development models—including independent R&D collaborations, investments, and mergers and acquisitions—Zhonghong Pulin is continuously iterating innovative product solutions, steadily advancing toward its vision of becoming a globally leading comprehensive supplier of medical health products and services.

Zhonghong Pulin Group (Stock Code: 300981) is a national high-tech enterprise, selected as one of the 200 “World-Class Specialized, Refined, Differential, and Innovative Demonstration Enterprises” by the State-owned Assets Supervision and Administration Commission of the State Council, and ranked among the Top 50 Listed Medical Device Companies in China. The company is engaged in the research and development, production, and sales of medical consumables and equipment, including high-quality disposable health protective products and sterile medical instruments. It operates three business divisions: Health Protection, Safe Infusion, and Innovation Incubation. With five major production bases and six R&D platforms across China, the company is committed to becoming a globally leading comprehensive supplier of medical health products and services.